Thrombosis and acute leukemia

References

• Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125:490–3.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH, James P. Frequency, risk factors, and trendsfor venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339–46.
   PubMed Web of Science ®Google Scholar
• Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110:167–72.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.
   PubMed Web of Science ®Google Scholar
• Imberti D, di Nisio M, Donati MB, Falanga A, Ghirarduzzi A, Guarneri D, et al.. Treatment of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2009;124:e32–40.
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009;123:837–44.
   PubMed Web of Science ®Google Scholar
• Ziegler S, Sperr WR, Knöbl P, Lehr S, Weltermann A, Jäger U, et al.. Symptomatic venous thromboembolism in acute leukemia: incidence, risk factors and impact on prognosis. Thromb Res. 2005;115:59–64.
   PubMed Web of Science ®Google Scholar
• Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A. Increased risk of venous thromboembolism in patients with acute leukemia. Br J Cancer. 2006;94:200–2.
   PubMed Web of Science ®Google Scholar
• de Stefano V, Sorà F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al.. The risk of thrombosis in patients with acute leukemia: ocurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3:1985–92.
   PubMed Web of Science ®Google Scholar
• Melillo L, Grandone E, Colaizzo D, Cappucci F, Valvano MR, Cascavilla N. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single center experience of 114 patients at diagnosis. Acta Haematol. 2007;117:215–20.
   PubMed Web of Science ®Google Scholar
• Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia. Incidence, risk factors and effect on survival. Blood. 2009;113:3911–7.
   PubMed Web of Science ®Google Scholar
• Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;11:125–31.
   Google Scholar
• Athale U, Siciliano S, Thabane L, Pai N, Cox S, Lathia A, et al.. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer. 2008;51:792–7.
   PubMed Web of Science ®Google Scholar
• Caruso V, Lacoviello L, di Castelnuevo A, Storti S, Mariani G, de Gaetano G, et al.. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–22.
   PubMed Web of Science ®Google Scholar
• Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukemia. Br J Haematol. 2007;138:430–45.
   PubMed Web of Science ®Google Scholar
• Korte W, Fledges A, Baumgartner C, Ullmann S, Niederer V, Schmid L. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin Padiatr. 1994;206:331–3.
   PubMed Web of Science ®Google Scholar
• Sutor AH, Mall V, Thomas KB. Bleeding and thrombosis in children with acute lymphoblastic leukemia, treated according to the ALL-BFM-90 ptrotocol. Klin Padiatr. 1999;211:201–4.
   PubMed Web of Science ®Google Scholar
• Nowak-Göttl U, Heinecke A, von Kries R, Nürnberger W, Münchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia. Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103:165–72.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, et al.. Improved outcome for children with acute lymphoblastic leukemia: results of the Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–8.
   PubMed Web of Science ®Google Scholar
• Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with ALL: risk of thrombotic complications in L-asparaginase induced antithrombin deficiency. Blood. 1994;83:386–91.
   PubMed Web of Science ®Google Scholar
• Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood ALL. Leuk Res. 2000;24:559–65.
   PubMed Web of Science ®Google Scholar
• Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, et al.. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastoc lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93;1488–94.
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al.. Prospective evaluation of the thrombotic risk in children with ALL carrying the MTHFR TT 677 genotype, the prothrombine G20210A variant and further prothrombotic risk factors. Blood. 1999;93:1595–9.
   PubMed Web of Science ®Google Scholar
• Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al.. A prospective cohort study determining the prevalence of thrombotic events in children with ALL and a central venous line who are treated with L-aparaginase: results of the Prophylactic Antithrombin Replacement in Kids with ALL Treated with sparaginase (PARKAA) study. Cancer. 2003;97:508–16.
   PubMed Web of Science ®Google Scholar
• Harlev D, Zaidman I, Sarig G, Ben Arush MW, Brenner B, Elhasid R. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res. 2010;126:93–7.
   PubMed Web of Science ®Google Scholar
• Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine (Baltimore). 1984;63:189–200.
   PubMed Web of Science ®Google Scholar
• Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infection complications of central venous catheters. JAMA. 1994;271:1014–6.
   PubMed Web of Science ®Google Scholar
• Balestreri L, de Cicco M, Matorio M, Coran F, Morassut S. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a plebography study. Eur J Radiol. 1995;20:108–11.
   PubMed Web of Science ®Google Scholar
• de Cicco M, Matorio M, Balstreri L, Panarello G, Fantin D, Morassut S, et al.. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catéter. A prospective study. Thromb Res. 1997;86:101–13.
   PubMed Web of Science ®Google Scholar
• Starkhammar H, Bengtsson M, Morales O. Fibrin sleeve formation after long term brachial catheterization with implantable port device. A prospective study. Eur J Surg. 1992;158:481–4.
   PubMedGoogle Scholar
• Raad I, Custerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization during of placement. J Infect Dis. 1993;168:400–7.
   PubMed Web of Science ®Google Scholar
• Tenney JH, Moody MR, Newman KA, Schimpff SC, Wade JC, Costerton JW, et al.. Adherent microorganisms on luminal surfaces of a long-term intravenous catheters. Importance of Staphylococcus epidermidis in patient with cancer. Arch Intern Med. 1986;146:1949–54.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. The Oncologist. 2004;9:207–16.
   PubMed Web of Science ®Google Scholar
• Hurtubise MR, Bottino JC, Lawson M, McCredie KB. Restoring patency of occluded central venous catheters. Arch Surg. 1980;115:212–3.
   PubMed Web of Science ®Google Scholar
• Beckers MM, Ruven HJ, Seldenrijk CA, Prins MH, Biesma DH. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res. 2010;125:318–21.
   PubMed Web of Science ®Google Scholar
• Oehadian A, Iqhal M, Sumantri R. Deep vein thrombosis in acute myelogenous leukemia. Acta Med Indones-Indones J Intern Med. 2009;41:200–4.
   PubMedGoogle Scholar
• Falanga A, Rickles FR. Management of thrombohemorrhagic syndrome (THS) in hematologic malignancies. Hematology. 2007;165–71.
   Google Scholar
• Falanga A, Marchetti M. Venous thromboembolism in the hematological malignancies. J Clin Oncol. 2009;27:4848–57.
   PubMed Web of Science ®Google Scholar
• Menell JS, Cesarman GM, Andrew T, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Eng J Med. 1999;340:994–1004.
   PubMed Web of Science ®Google Scholar
• Liu YH, Wang ZY, Shen WH. Influence of arsenic trioxide and daunorubicin on the expression of annexin II and fibrinolytic activity in NB4 cells. Zhongua Xue Ye Xue Za Zhi. 2010;12:813–6. Chinese.
   Google Scholar
• Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia Thromb Res. 2010;125 Suppl 2:S51–4.
   Google Scholar
• Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia — a single center experience in 34 patients. Thromb Res. 2005;116:109–14.
   PubMed Web of Science ®Google Scholar
• Kwaan HC, Huyck T. Thromboembolic and bleeding complications in acute leukemia. Expert Rev Hematol. 2010;6:719–30.
   Google Scholar
• Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, de Propris MS, et al.. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotyping and molecular features. Leukemia. 2007;21:79–83.
   PubMed Web of Science ®Google Scholar
• Montesinos P, de la Serna J, Vellenga E, Rayon C, Bergua J, Parody R, et al.. Incidence and risk factors for thrombosis in patients with acute promyelocytic leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols. Blood (ASH Ann Meet Abstr). 2006;108:1503.
   Web of Science ®Google Scholar